OM
Outset Medical, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
4.21
▼ 0.09 (2.09%)
MARKET · —
Price
Open
4.31
Prev close
4.30
Day high
4.45
Day low
4.16
Volume
148.83K
Market cap
$79.14M
P/E (TTM)
—
52W range
3.00 – 16.16
Trailing performance
Returnvs SPY
1W
-6.65%
-5.3%
1M
-0.47%
-4.2%
3M
-1.17%
-4.3%
6M
+19.26%
+8.2%
YTD
+13.48%
+1.2%
1Y
-68.44%
-88.4%
3Y
-98.10%
-172.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$79.14M
Enterprise value$36.39M
Revenue (TTM)$117.80M
Gross profit$49.20M
EBITDA$-62.73M
Net income$-74.29M
EPS (TTM)$-3.80
Free cash flow$-14.68M
Total cash$147.19M
Total debt$104.45M
Book value / share$5.13
Shares outstanding18.80M
Float14.77M
Short % of float8.22%
Dividend yield—
Beta (5Y)1.92
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.84
PEG ratio—
Price / sales—
Price / book0.82
EV / revenue0.31
EV / EBITDA-0.58
Gross margin41.76%
Operating margin-49.55%
Profit margin-63.06%
Return on equity-59.17%
Return on assets-15.54%
Debt / equity108.42
Current ratio5.19
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $119.48M | $113.69M | $130.00M | $115.38M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$81.65M | -$127.98M | -$172.80M | -$162.96M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$81.65M | -$127.98M | -$172.80M | -$162.96M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.72 | -0.80 | -11.6% |
| Mar 2026 | -0.79 | -0.83 | -5.1% |
| Dec 2025 | -0.68 | -0.84 | -24.4% |
| Sep 2025 | -0.66 | -0.69 | -5.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.69 | 3 | $31.40M | +6.7% |
| Next quarter | -0.69 | 3 | $35.03M | +21.3% |
| Current year | -3.09 | 3 | $125.97M | +5.4% |
| Next year | -2.29 | 3 | $139.10M | +10.4% |
Analyst targets & ownership
Mean target$7.67
High target$10.00
Low target$6.00
Implied upside82.11%
Analyst count3
ConsensusBUY
Strong buy / Buy0 / 2
Hold1
Sell / Strong sell0 / 0
Held by insiders4.94%
Held by institutions73.95%
Institutions holding126
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+1.17M
Net buying
Buy transactions
13
1.21M shares
Sell transactions
8
36.63K shares
Net transactions
+21
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
929.33K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 17, 26 | TRIGG LESLIE L Chief Executive Officer |
SELL | 3.44K | $15.09K | Direct |
| Aug 17, 26 | GAETA RENEE Chief Financial Officer |
SELL | 4.54K | $19.94K | Direct |
| Aug 17, 26 | BROTTEM JOHN L. General Counsel |
SELL | 2.63K | $11.55K | Direct |
| Jun 26, 26 | TRIGG LESLIE L Chief Executive Officer |
STOCK | 99.16K | $0 | Direct |
| Jun 26, 26 | GAETA RENEE Chief Financial Officer |
STOCK | 71.63K | $0 | Direct |
| Jun 26, 26 | BROTTEM JOHN L. General Counsel |
STOCK | 59.83K | $0 | Direct |
| Jun 4, 26 | GROSSMAN DONALD KEITH Director |
STOCK | 10.67K | $0 | Direct |
| Jun 4, 26 | HACKETT PATRICK T. Director |
STOCK | 10.67K | $0 | Direct |
| Jun 4, 26 | DREXLER KAREN Director |
STOCK | 10.67K | $0 | Direct |
| Jun 4, 26 | LANG BRENT D Director |
STOCK | 10.67K | $0 | Direct |
| Jun 4, 26 | PRANGE KAREN N. Director |
STOCK | 10.67K | $0 | Direct |
| Jun 4, 26 | O'BOYLE KEVIN C Director |
STOCK | 10.67K | $0 | Direct |
| Jun 3, 26 | GAETA RENEE Chief Financial Officer |
SELL | 17.67K | $87.30K | Direct |
| May 15, 26 | NASH MARC Officer |
SELL | 1.58K | $5.85K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BROTTEM JOHN L. |
General Counsel | 87.47K | Sale |
ELLIOTT DERICK A |
Officer | 96.00K | Stock Award(Grant) |
GAETA RENEE |
Chief Financial Officer | 180.84K | Sale |
GROSSMAN DONALD KEITH |
Director | 37.43K | Stock Award(Grant) |
HACKETT PATRICK T. |
Director | 230.84K | Stock Award(Grant) |
LANG BRENT D |
Director | 45.18K | Stock Award(Grant) |
LEONARD BRADEN MICHAEL |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
NASH MARC |
Officer | 38.39K | Sale |
O'BOYLE KEVIN C |
Director | 34.78K | Stock Award(Grant) |
TRIGG LESLIE L |
Chief Executive Officer | 236.85K | Sale |
Moving averages & technicals
SMA 10
4.45
-5.41% from price
SMA 20
4.65
-9.42% from price
SMA 50
4.54
-7.30% from price
SMA 100
4.43
-5.06% from price
SMA 200
4.50
-6.44% from price
EMA 12
4.45
-5.42% from price
EMA 26
4.52
-6.93% from price
EMA 50
4.51
-6.73% from price
RSI (14)
42.8
Neutral
MACD (12,26,9)
-0.07
Hist -0.07
ATR (14)
0.41
9.74% of price
Realised vol 30D
68.6%
Annualised
Bollinger upper
5.30
20, 2σ
Bollinger lower
3.99
20, 2σ
50 / 200 cross
Golden
4.54 vs 4.50
Trend bias
Below 200
-6.44%
Risk profile
Beta vs SPY
2.09
More volatile than market
Correlation to SPY
0.27
Largely independent
Realised vol 30D
68.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-80.0%
Peak to trough
Max drawdown 5Y
-99.6%
Peak to trough
ATR 14
0.41
9.74% of price
Beta (reported)
1.92
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
4.29
Positioning, not flow
Max pain
2.50
-40.6% from spot
ATM implied vol
79.7%
Nearest strike to spot
Skew (10% OTM)
+214.8%
Puts bid over calls
Call volume
50
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
5.00
7 contracts
Heaviest put OI
2.50
30 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Despite Fast-paced Momentum, Outset Medical (OM) Is Still a Bargain Stock
Zacks · 4d ago
Outset Medical (OM) Q2 2026 Earnings Call Transcript
Motley Fool · 9d ago
Outset Medical Q2 Earnings Call Highlights
MarketBeat · 15d ago
Outset Medical Inc (OM) (Q2 2026) Earnings Call Highlights: Revenue Growth and Strategic HCA ...
GuruFocus.com · 15d ago
Outset Medical, Inc. (OM) Reports Q2 Loss, Beats Revenue Estimates
Zacks · 16d ago
Outset Medical Reports Second Quarter 2026 Results
GlobeNewswire · 16d ago
Earnings To Watch: Outset Medical Inc (OM) Q2 2026 -- GF Value Sees 12% Downside
GuruFocus.com · 17d ago
Outset Medical to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
GlobeNewswire · 30d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.